KNF approves OncoArendi IPO prospectus

The Financial Supervision Authority approved the IPO prospectus of a biotechnological firm OncoArendi Therapeutics, which specializes in oncological pharmaceuticals. The company plans to offer 500k-2 million new shares under its IPO planned for the turn of March and April, the company said. “The company’s intention is to offer some 90 percent of shares to institutional…

This content is for Silver 6 months, Gold 1 Year and Bronze 2 weeks members only.
Log In Buy Subscription
Pin It